BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parikh SV, Rovin BH. Current and Emerging Therapies for Lupus Nephritis. J Am Soc Nephrol 2016;27:2929-39. [PMID: 27283496 DOI: 10.1681/ASN.2016040415] [Cited by in Crossref: 44] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Fontana F, Alfano G, Leonelli M, Cerami C, Ligabue G, Spinella A, Citriniti G, Manzini CU, Ferri C, Cappelli G. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report. BMC Nephrol 2018;19:276. [PMID: 30342482 DOI: 10.1186/s12882-018-1066-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
2 Obrișcă B, Sorohan B, Tuță L, Ismail G. Advances in Lupus Nephritis Pathogenesis: From Bench to Bedside. Int J Mol Sci 2021;22:3766. [PMID: 33916456 DOI: 10.3390/ijms22073766] [Reference Citation Analysis]
3 Khattab NM, Abbassi M, A Raafat H, Farid S. A pharmacoeconomic study comparing the use of mycophenolate mofetil or cyclophosphamide as induction therapy in lupus nephritis patients in Egypt. Lupus 2022;:9612033221083270. [PMID: 35254887 DOI: 10.1177/09612033221083270] [Reference Citation Analysis]
4 Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017;12:825-835. [PMID: 27821390 DOI: 10.2215/cjn.05780616] [Cited by in Crossref: 291] [Cited by in F6Publishing: 137] [Article Influence: 48.5] [Reference Citation Analysis]
5 Chi M, Ma K, Wang J, Ding Z, Li Y, Zhu S, Liang X, Zhang Q, Song L, Liu C. The Immunomodulatory Effect of the Gut Microbiota in Kidney Disease. J Immunol Res 2021;2021:5516035. [PMID: 34095319 DOI: 10.1155/2021/5516035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 An Y, Zhang H, Liu Z. Individualizing Therapy in Lupus Nephritis. Kidney Int Rep 2019;4:1366-72. [PMID: 31701046 DOI: 10.1016/j.ekir.2019.08.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Ubara Y, Kawaguchi T, Nagasawa T, Miura K, Katsuno T, Morikawa T, Ishikawa E, Ogura M, Matsumura H, Kurayama R, Matsumoto S, Marui Y, Hara S, Maruyama S, Narita I, Okada H, Tsuruya K; Committee of Practical Guide for Kidney Biopsy 2020. Kidney biopsy guidebook 2020 in Japan. Clin Exp Nephrol 2021;25:325-64. [PMID: 33606126 DOI: 10.1007/s10157-020-01986-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13:483-495. [PMID: 28669995 DOI: 10.1038/nrneph.2017.85] [Cited by in Crossref: 105] [Cited by in F6Publishing: 93] [Article Influence: 21.0] [Reference Citation Analysis]
9 Brady MP, Korte EA, Caster DJ, Powell DW. TNIP1/ABIN1 and lupus nephritis: review. Lupus Sci Med 2020;7:e000437. [PMID: 33122334 DOI: 10.1136/lupus-2020-000437] [Reference Citation Analysis]
10 Bolouri N, Akhtari M, Farhadi E, Mansouri R, Faezi ST, Jamshidi A, Mahmoudi M. Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus. Inflamm Res 2022. [PMID: 35298669 DOI: 10.1007/s00011-022-01554-6] [Reference Citation Analysis]
11 Obrișcă B, Vornicu A, Jurubiță R, Achim C, Bobeică R, Andronesi A, Sorohan B, Herlea V, Procop A, Dina C, Ismail G. Corticosteroids are the major contributors to the risk for serious infections in autoimmune disorders with severe renal involvement. Clin Rheumatol 2021;40:3285-97. [PMID: 33595739 DOI: 10.1007/s10067-021-05646-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Krassanairawiwong K, Charoenpitakchai M, Supasyndh O, Satirapoj B. Revised ISN/RPS 2018 classification of lupus renal pathology predict clinical remission. Int Urol Nephrol 2021;53:1391-8. [PMID: 33682052 DOI: 10.1007/s11255-020-02732-3] [Reference Citation Analysis]
13 Kraaij T, Arends EJ, van Dam LS, Kamerling SWA, van Daele PLA, Bredewold OW, Ray A, Bakker JA, Scherer HU, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant 2021;36:1474-83. [PMID: 32591783 DOI: 10.1093/ndt/gfaa117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
14 Wang L, Lin W, Chen J. Krüppel-like Factor 15: A Potential Therapeutic Target For Kidney Disease. Int J Biol Sci 2019;15:1955-61. [PMID: 31523196 DOI: 10.7150/ijbs.34838] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Browning SG. The Roles of Systemic Lupus Erythematosus and Immunoglobulin A Nephropathy in Glomerular Disease. Nurs Clin North Am 2018;53:531-9. [PMID: 30388979 DOI: 10.1016/j.cnur.2018.07.004] [Reference Citation Analysis]
16 Caster DJ, Merchant ML, Klein JB, Powell DW. Precision medicine in lupus nephritis: can biomarkers get us there? Transl Res 2018;201:26-39. [PMID: 30179587 DOI: 10.1016/j.trsl.2018.08.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
17 Almaani S, Rovin BH. B-cell therapy in lupus nephritis: an overview. Nephrol Dial Transplant 2019;34:22-9. [PMID: 30165690 DOI: 10.1093/ndt/gfy267] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
18 Hong S, Healy H, Kassianos AJ. The Emerging Role of Renal Tubular Epithelial Cells in the Immunological Pathophysiology of Lupus Nephritis. Front Immunol 2020;11:578952. [PMID: 33072122 DOI: 10.3389/fimmu.2020.578952] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
19 Ayoub I, Nelson J, Rovin BH. Induction Therapy for Lupus Nephritis: the Highlights. Curr Rheumatol Rep 2018;20:60. [PMID: 30109511 DOI: 10.1007/s11926-018-0766-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
20 Caster DJ, Powell DW. Utilization of Biomarkers in Lupus Nephritis. Adv Chronic Kidney Dis 2019;26:351-9. [PMID: 31733719 DOI: 10.1053/j.ackd.2019.09.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]